BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 15534180)

  • 1. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
    McArthur JC; McDermott MP; McClernon D; St Hillaire C; Conant K; Marder K; Schifitto G; Selnes OA; Sacktor N; Stern Y; Albert SM; Kieburtz K; deMarcaida JA; Cohen B; Epstein LG
    Arch Neurol; 2004 Nov; 61(11):1687-96. PubMed ID: 15534180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain.
    McArthur JC; McClernon DR; Cronin MF; Nance-Sproson TE; Saah AJ; St Clair M; Lanier ER
    Ann Neurol; 1997 Nov; 42(5):689-98. PubMed ID: 9392567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.
    Ellis RJ; Hsia K; Spector SA; Nelson JA; Heaton RK; Wallace MR; Abramson I; Atkinson JH; Grant I; McCutchan JA
    Ann Neurol; 1997 Nov; 42(5):679-88. PubMed ID: 9392566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people.
    Vitiello B; Goodkin K; Ashtana D; Shapshak P; Atkinson JH; Heseltine PN; Eaton E; Heaton R; Lyman WD
    AIDS; 2007 Jul; 21(11):1415-22. PubMed ID: 17589187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.
    Sevigny JJ; Albert SM; McDermott MP; Schifitto G; McArthur JC; Sacktor N; Conant K; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Marder K; Epstein LG
    Arch Neurol; 2007 Jan; 64(1):97-102. PubMed ID: 17210815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of immune activation and viral load in HIV-associated sensory neuropathy.
    Schifitto G; McDermott MP; McArthur JC; Marder K; Sacktor N; McClernon DR; Conant K; Cohen B; Epstein LG; Kieburtz K;
    Neurology; 2005 Mar; 64(5):842-8. PubMed ID: 15753420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.
    McCutchan JA; Wu JW; Robertson K; Koletar SL; Ellis RJ; Cohn S; Taylor M; Woods S; Heaton R; Currier J; Williams PL
    AIDS; 2007 May; 21(9):1109-17. PubMed ID: 17502721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
    Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
    Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
    Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.